Payment overview · 2025
General Payments
$549.73
21 reported records · 11 companies
Healthcare provider profile · identity verified
Paul Michael Rutkowski, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · DUPONT, PA · NPI 1003078254
Verified facts
What the public records show
CMS Open Payments records show Paul Michael Rutkowski, D.O. received $549.73 in general payments during 2025 across 21 reported records.
Medtronic, Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$171.23 | 31.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.02 | 29.6% | 8 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.17 | 6.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.07 | 6.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.11 | 6.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.00 | 3.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.31 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.80 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.57 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.67 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.78 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.73 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $171.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.48 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $80.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $71.18 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.17 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 633 | 148 |
| Alprazolam | Alprazolam | 517 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 305 | 72 |
| Lisinopril | Lisinopril | 266 | 72 |
| Omeprazole | Omeprazole | 258 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 35 |
| Gabapentin | Gabapentin | 220 | 53 |
| Metformin Hcl | Metformin Hcl | 217 | 53 |
| Furosemide | Furosemide | 215 | 56 |
| Losartan Potassium | Losartan Potassium | 187 | 53 |
| Meloxicam | Meloxicam | 185 | 46 |
| Simvastatin | Simvastatin | 175 | 39 |
| Potassium Chloride | Potassium Chloride | 164 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 45 |
| Carvedilol | Carvedilol | 147 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 45 |
| Montelukast Sodium | Montelukast Sodium | 147 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 35 |
| Eliquis | Apixaban | 142 | 31 |
| Prednisone | Prednisone | 135 | 96 |
| Famotidine | Famotidine | 125 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 125 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 22 |
| Azithromycin | Azithromycin | 117 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 29 |
| Clonazepam | Clonazepam | 115 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 36 |
| Buspirone Hcl | Buspirone Hcl | 101 | 24 |
| Glimepiride | Glimepiride | 100 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 96 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 91 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 33 |
| Atenolol | Atenolol | 89 | 28 |
| Sertraline Hcl | Sertraline Hcl | 89 | 18 |
| Allopurinol | Allopurinol | 85 | 28 |
| Warfarin Sodium | Warfarin Sodium | 81 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 15 |
| Baclofen | Baclofen | 69 | 19 |
| Trazodone Hcl | Trazodone Hcl | 67 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 34 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 59 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 59 | 11 |
| Paliperidone Er | Paliperidone | 58 | suppressed |
| Bupropion Xl | Bupropion Hcl | 57 | 13 |
| Lovastatin | Lovastatin | 57 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Sucralfate | Sucralfate | 51 | 21 |
| Diazepam | Diazepam | 50 | suppressed |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Valsartan | Valsartan | 44 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | 11 |
| Glipizide | Glipizide | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 33 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 35 | suppressed |
| Dutasteride | Dutasteride | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Sotalol | Sotalol Hcl | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Acetazolamide | Acetazolamide | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Roflumilast | Roflumilast | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.73 · 21 records | Medtronic, Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, SYMPLICITY G3, TRELEGY ELLIPTA, Tymlos, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error